Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Neoplasms × larotrectinib × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Central Nervous System Neoplasms 3 Wilms Tumor 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Xanthogranuloma, Juvenile 1 Sarcoma, Ewing 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma 1 Histiocytic Sarcoma 1

Interventions

pembrolizumab 27 Cyclophosphamide 17 Nivolumab 16 fludarabine 8 Surveys and Questionnaires 8 Paclitaxel 8 Exercise 8 Doxorubicin 8 Carboplatin 8 Bevacizumab 8 budigalimab 7 atezolizumab 7 Radiotherapy 7 Fluorouracil 7 Docetaxel 7 Dexamethasone 7 Blood Specimen Collection 7 venetoclax 6 lenvatinib 6 cabozantinib 6 Rituximab 6 Prednisone 6 Pemetrexed 6 Oxaliplatin 6 Gemcitabine 6 fludarabine phosphate 5 durvalumab 5 avelumab 5 Vincristine 5 Leucovorin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting

154 enrolled 3 FDA

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡